METRALINDOLE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H17N3O
Molecular Weight	255.315
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C2N3CCN(C)C4=NCCC(C2=C1)=C34

InChI

InChIKey=GVXBHSBKKJRBMS-UHFFFAOYSA-N

InChI=1S/C15H17N3O/c1-17-7-8-18-13-4-3-10(19-2)9-12(13)11-5-6-16-15(17)14(11)18/h3-4,9H,5-8H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C15H17N3O
Molecular Weight	255.315
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1884793 | https://link.springer.com/article/10.1007/BF00781063 | https://www.ncbi.nlm.nih.gov/pubmed/4043371

Metralindole (Inkazan) is a reversible inhibitor of monoamine oxidase A (RIMA) which was used in Russia as an antidepressant. Inkasan (3-methyl-8-methoxy-3H, 1,2,5,6- tetrahydropyrazine /1.2.3-ab/-beta-carboline hydrochloride) has pharmacological properties characteristic of antidepressants. The clinical antidepressant effect of inkasan is combined with stimulating action. The drug is primarily indicated for patients in whom adynamic (anergic) disturbances are predominant in the clinical picture of depression.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Monoamine oxidase A 49 Target ID: CHEMBL3358 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1884793	Inhibitor 8297
Monoamine oxidase A 49 Target ID: CHEMBL3358 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1884793	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Depression 235 Sources: http://provizor-online.ru/2013/03/inkazan_Incazanum https://www.ncbi.nlm.nih.gov/pubmed/2728714 https://www.ncbi.nlm.nih.gov/pubmed/4043371	Primary		Approved 8429	Inkazan Approved Use Treatment of depression. The drug is primarily indicated for patients in whom adynamic (anergic) disturbances are predominant in the clinical picture of depression.

PubMed

Title	Date	PubMed
Cellular and humoral IgA responses after single and multiple local injections of antigen.	1983 Apr 15	6682716
[The comparative influence of pyrazidol, inkazan and other antidepressant monoamine oxidase inhibitors on the pressor effect of tyramine].	1991 Mar-Apr	1884793
Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.	2003 Sep 22	14504114

Patents

Sample Use Guides

In Vivo Use Guide

Cats: Electroencephalographic investigations conducted by L. F. Roshchina showed that in cats inkazan in doses of 10-40 mg/kg (intravenously) caused increased cortical and subcortical activity and intensified the reaction of cortex to photo- and photon stimulation. The electrophysiological response of inkazan persists for 3-4 h. In doses of 5-50 mg/kg administered intraperitoneally, the preparation slows conditioned reflexes of avoidance in rats.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:21:41 UTC 2023` Edited by `admin` on `Fri Dec 15 16:21:41 UTC 2023`
Record UNII	2QW3FL6OPA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

METRALINDOLE

Official Name

English

metralindole [INN]

Common Name

English

METRALINDOLE [MI]

Common Name

English

2,4,5,6-TETRAHYDRO-9-METHOXY-4-METHYL-1H-3,4,6A-TRIAZAFLUORANTHENE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C265